AXAxos Financial, Inc.

AX — Axos Financial, Inc. — dossier, 2026-09-22

Slot names-insurance-1 (Tier 0 promotion). Model-drafted unattended by the cloud research routine (Opus 5), following .claude/skills/stock-sourcing-pipeline/SKILL.md. Nothing here is human-verified. Sourced facts carry the document they were read from; [background] marks background knowledge and [search-summary] marks search-derived material. Private: this directory never reaches dist/.

Access this run is recorded once in ACGL/dossier-2026-09-22.md and applies identically here: EDGAR and 3spread reachable, Equibles unreachable (connector failed to connect), ROIC prices yes / calendar paid, fool.com reachable but carrying no Axos transcript.

Why this name is here. queue.json promoted AX on 2026-09-22 at priority 2 for an "8-K filed 2026-09-21 (current report)". Under the skill's promotion rule a promoted name with no scorecard.md replaces the last member of the slot's batch, so AX took RYAN's place in names-insurance-1; RYAN returns to a later insurance slot. Two other names remain promoted and unhandled: PUMP (priority 2) and SNDK (priority 4). The skill also says a promoted name was promoted for a reason and that reason is the lead for the run. It was.

§1 — The finding: the deal closed 41% smaller than it was signed, and no filing says why

Three filings, one transaction, in date order:

$1.3 billion, 41% of the agreed book, did not arrive, and neither the completion 8-K nor anything else on the index quantifies, explains or even acknowledges the difference. The completion filing is four sentences long.

The ordinary explanation is benign and probably right: deposit purchase and assumption agreements are customarily struck on a balance measured around signing, with the actual transfer sized at closing, so five months of IRA attrition — customers who move rather than be transferred to a bank they did not choose — reduces what changes hands. Nobody is at fault in that story. But the size is what makes it a finding. A 5% or 10% slippage is attrition; 41% over five months on a book of IRA savings and CDs — among the stickiest retail deposits that exist, since moving one is a custodial transfer with tax paperwork — is a different order of number, and the company chose not to address it in the filing that announced the close.

Why it matters to this name in particular. Axos's FY2026 headline deposit growth was $3.7bn, +17.9%, and the results release says so in a bullet that also says $2.3bn of it was bought (the Jenius Bank consumer book, closed 2026-05-02). Organic deposit growth was therefore about $1.4bn, roughly 6.7%. Acquired deposits are the funding growth story at this bank, and on its largest such transaction the machine delivered 59% of what was announced. That is not a credit event or an accounting concern. It is a question about the durability of the growth algorithm, and it is the single thing the next 10-Q can answer.

Note also what the premium is: unknown. Both 8-Ks say the Bank receives cash for the deposits "less a negotiated premium" and neither discloses the rate, so the cost per dollar of what actually arrived cannot be computed from the public record.

§2 — The second finding: a $49m award accrued at $21m

Buried in the contingencies note, not in the release, not in the MD&A narrative:

"Other Matters. On June 5, 2026, a FINRA arbitration panel rendered an award of approximately $ 49 million against Axos Clearing, a downstream subsidiary of Axos Financial in the FINRA arbitration forum styled Acquarulo et al. v. Axos Clearing LLC ."

The matter arose from clearing services Axos Clearing provided to a third-party introducing broker-dealer "which is alleged to have committed certain sales practice violations"; Axos Clearing asserts it had no duty to supervise that firm's sales practices, has filed a petition to vacate, and:

"Axos Clearing has filed a petition to vacate the award and, based on its assessment of the likelihood of potential outcomes, the Company has accrued a liability of $ 21 million in “General and administrative expense” in the Consolidated Statement of Income for the year ended June 30, 2026."

So $21m of a ~$49m award is accrued — 43% — and the remaining ~$28m (≈$0.49 per share before tax) rests on the vacatur succeeding. That is a disclosed, quantified, binary contingency with a court date attached, and it is not mentioned in the earnings release except as an expense the CFO backs out.

The $21m that was taken is not small either: it is $0.36 of the $8.48 diluted EPS (the company's own non-GAAP bridge says so), and it is the entire explanation of the Securities Business Segment's 23.1% rise in non-interest expense. In the same expense bullet sits a second legal accrual — $7.0m "for developments in a matter related to the Company's acquisition of COR Securities in fiscal year 2019". Two litigation accruals in the clearing business in one fiscal year is worth a line in the next pass; it is not yet a thesis.

§3 — S2 kill test

(XBRL companyconcept, CIK 1299709. FY2024's $7.66 EPS includes a $92.4m gain on the FDIC loan purchase, $1.57/share, which is why FY2025 looks like a decline and is not one.)

Share count over five years: 61.90m (FY2019) → 56.66m (FY2026), −8.5%, entirely through modest repurchase, no issuance anywhere. Clean.

The ratios, which tell a different story from the earnings line (10-K Item 7, three-year selected-ratio table):

Earnings up 13%, and returns, margin, efficiency and bank capital all moving the other way. Assets grew 20.9% in a year while the Bank's CET1 fell 149bp; Axos is growing its balance sheet faster than it generates capital and returns almost none of what it earns ($22.0m of buyback against $490.4m of net income).

Three things that make FY2026 earnings lower-quality than the headline. All three are in the filings and none is in the release's framing:

1. Non-interest income +78.2% to $233.6m is attributed to three things: Verdant operating-lease rental income, "A $22.0 million legal settlement in our favor reached in March 2026" — a one-off, and the company's own non-GAAP bridge removes it — and rental income from a commercial office complex the Company bought for ~$125m in January 2026 and intends to occupy itself. The Verdant lease income arrives with its own cost: depreciation and amortisation rose from $29.0m to $80.6m, +$51.6m, "primarily due to depreciation on equipment under operating leases following the Verdant acquisition".
2. The FDIC purchased-loan book is running off, at a 16% yield. Average balance $973.1m (FY2025) → $712.7m (FY2026), interest income $160.6m → $115.4m, yield 16.51% → 16.19%. That is a $45m/year disclosed and dated headwind on a pre-tax base of about $750m, and another $40-50m is likely in FY2027 on the same trajectory. Nothing in the reported guidance replaces it; the new loan book yields 7.44%.
3. $28m of the FINRA award is unaccrued (§2).

Survives or dies: survives, with room and without drama. A 10.57% equity/assets ratio, a Bank CET1 of 10.93% against a 7% requirement [background], non-performing assets at 0.53% of assets and falling, an allowance covering nonaccruals 2.2x, and $490m of annual earnings against no holding company funding stress. The question this name poses is not solvency; it is whether a 16% ROE franchise is on its way to a 13% one.

§4 — S3 gate: the three biggest risks management itself discloses

Axos's Item 1A is grouped rather than ranked, so these are chosen by the size of the disclosed exposure, not by position — and each is quantified by the company.

1. Geographic real-estate concentration. "At June 30, 2026, approximately 37.4% and 33.5% of our real estate loan portfolio was secured by real estate located in New York and California, respectively." (Item 1A, "Declining real estate values, particularly in California and New York, could reduce the value of our loan and lease portfolio…") Seventy-one per cent of the real estate book in two states, on a balance sheet where real estate secures the majority of loans.
2. Multifamily. "At June 30, 2026, our multifamily residential loans were $2.5 billion or 9.5% of our loan portfolio." (Item 1A, "Many of our mortgage loans are multifamily residential loans and defaults on such loans would harm our business.") New York multifamily has its own rent-regulation story [background] and the company's own disclosure puts the concentration and the geography in adjacent risk factors.
3. Interest rates — placed first in the whole item. "Changes in interest rates could adversely affect our performance." is the opening risk factor of Item 1A, under "Risks Relating to Macroeconomic Conditions". For a bank running a 4.70% NIM off floating-rate commercial assets funded with retail deposits, this is the single largest swing factor in the P&L and management ranks it first.

The loan book, and the timing risk inside it (Item 7, loan portfolio composition and maturity tables):

The mix moved hard in one year: CRE +27.8%, C&I non-RE +39.7% (including Verdant), while multifamily shrank 15.5%. And the maturity table adds the part a composition table hides: of the $8,867.9m of commercial real estate, $576.0m matures in under three months and $1,964.7m within a year — $2,540.7m, 29% of the CRE book, refinancing inside twelve months, with none of it scheduled beyond five years. Short-dated CRE concentrated in New York and California is precisely the exposure BDO's critical audit matter points at.

Auditor and red-flag sweep. BDO USA, P.C., PCAOB ID 243, San Diego. Sole critical audit matter: the allowance for credit losses, $347,375 thousand at 2026-06-30, and specifically management's "significant judgments regarding the weighting of the economic forecast scenarios within the Commercial Real Estate (including construction lending) and Com[mercial]" portfolios. ⚠️ The FY2026 internal-control opinion excludes Verdant: "Verdant Commercial Capital, LLC constituted 6% of total assets, as of June 30, 2026, and 7% of net revenues for the year then ended", and management did not assess it either. That is a permitted first-year scope exclusion, not a finding — but 7% of FY2026 revenue sits outside both ICFR opinions and the next 10-K will be the first to cover it.

Filing index back to 2010: one NT 10-K, filed 2022-08-30 (FY2022 late filing) — four years ago and not repeated; SEC comment-letter correspondence in 2018 and again in 2023, the most recent exchange closing 2023-04-27; no 10-K/A and no 10-Q/A. Of the three names in this slot, AX is the only one with a late-filing notification in its history, and it is old.

§5 — S5 ownership

13F holders at 2026-06-30 (threespread.py holders AX): BlackRock 8,389,477 sh / $817.1m (+68,179); State Street 3,023,908 / $294.5m (+207,211); Charles Schwab IM 751,934 (+19,853); Ameriprise 654,362 (−762,616); Invesco 617,610 (+71,304); Emerald 536,162; Wasatch 515,576 (−100,805); Geneva 477,009 (−131,072); Wellington 470,586 (−367,267); Goldman Sachs 453,375; Citadel 423,753 (+323,663); Kennedy Capital 426,294 (+194,907).

⚠️ Quarter incompletely ingested — 235 filers against 382; both Vanguard entities (4.91m and 3.09m shares), American Century (2.51m), FMR (2.44m), Dimensional (2.18m), Geode (1.96m), Davis (1.54m), Franklin, Northern Trust and Morgan Stanley carry no filing in it. No exit may be read from an absence.

⚠️⚠️ The Sixth Street row (751,934 shares, $73.2m, "NEW", identical to Schwab's) is not a holding — the filing defect documented in ACGL/dossier-2026-09-22.md §5 and now warned on mechanically by threespread.py.

13D/G: all 13G, no 13D, no activist. A 13G/A filed 2026-03-26 sits in the same window as the Vanguard internal realignment documented in the APH pass (names-ai-capex-3), which is the known cause of Vanguard disappearing from 13F tables across issuers — worth remembering before reading Vanguard's absence here as anything.

Proxy (DEF 14A 2025-09-25, as of 2025-09-16): BlackRock 8,329,879 = 14.72%, The Vanguard Group 5,985,476 = 10.58%, on 56,595,223 shares outstanding. "All current directors and executive officers as a group (20 persons) (8)" hold 2,746,375 = 4.85% — the best insider alignment of the three names in this slot (ACGL 3.3% across 17, KNSL 5.6% across 14 but 4.0% of that is one person). ⚠️ this is the FY2025 proxy; the FY2026 one was not on the index when this pass ran.

Shelf / ATM / buyback. A 424B5 prospectus supplement was filed 2025-09-17 off an existing registration, so a shelf exists and has been used. Buyback: $22.0m of common stock repurchased in the whole of FY2026 against $490.4m of net income — under 5% of earnings. This is a capital-consuming grower and the Bank's CET1 says why it has to be.

§6 — S8 valuation and sizing (proposals only — ⏳ OPEN (user))

Price $90.63 at 2026-09-21 (ROIC NYSE:AX). Shares 56.734m → market cap $5.14bn. Equity $3,166.4m → BVPS $55.81, P/B 1.62. FY2026 diluted EPS $8.48 → P/E 10.7x (10.4x on the company's $8.74 adjusted EPS). ADV $35.1m over the 21 sessions to 2026-09-21 — the thinnest name this rotation has passed.

Assumptions, named: earning assets grow ~10% in FY2027 on the $1.9bn of acquired IRAs plus organic loan growth and ~8% in FY2028; NIM 4.70% → 4.55% → 4.50% as the 16%-yielding purchased-loan book runs off and acquired deposits reprice; non-interest income flat at ~$230m in FY2027 (the $22.0m settlement does not repeat, Verdant lease income annualises); efficiency ratio held near 49.5%; provision normalising toward a 0.25% charge-off rate plus reserve build on growth; tax 28%.

At $90.63: 10.7x FY2026A, 10.0x FY2027E, 9.0x FY2028E, and 1.22x the modelled FY2028 book.

Base is +21% over ~2 years, which — for the first time in nine names in this rotation — is a positive expected return at the traded price. It is also the widest bear case, because a bank is the one business model in this repository where the downside is not a de-rating but a capital event, and 29% of a $8.9bn CRE book refinances within a year.

Proposed buy price and size: ⏳ OPEN (user). The constraint the owner needs: ADV $35.1m/day. At 10% of daily volume a position takes three days per $10m to build or exit. This is the first name in the rotation where liquidity, not conviction, is likely to set the size.

§7 — S9 monitoring

• Next earnings ~2026-10-29, DERIVED from filing cadence. Fiscal Q1 results 8-Ks went out 2025-10-30 and 2024-10-30, with the 10-Q the same day. Not a scheduled date — ROIC.ai's calendar needs a paid plan and Equibles did not connect.
• Filing feed: the Tier 0 EDGAR sweep covers CIK 1299709 and has already demonstrated its value on this name — the 8-K that produced this run's finding is invisible in every periodic filing.
• Leading indicator between quarters: weekly H.8 commercial bank deposit data and the advertised rates on Axos's own high-yield savings products [background on the mechanism; no rate was read this pass]. A bank that has just replaced $1.9bn of purchased IRAs and needs to fund a 10% asset growth rate will show it in price before it shows it in the NIM.
• The specific trigger that converts this to a buy: two consecutive quarters in which the efficiency ratio stops rising and the net interest margin holds above 4.55%, with charge-offs still under 0.25% and Bank CET1 stabilised at or above 11%. That combination would say the FY2026 deterioration was the cost of digesting Verdant, Jenius and Capital One rather than the start of a trend — and at 10x earnings the market is not paying for it.

§8 — Evidence that is thin, named

• No earnings-call transcript. Equibles did not connect; no Axos transcript was located on fool.com. This is the third name in the slot without one and the first where none exists at the fallback rung either. Management commentary here comes entirely from the results release and the filings.
• S0, S4, S6 and S7 are not done — cluster-financials-global has not run, and the skill forbids improvising cluster stages per name. So there is no scuttlebutt of any kind for AX in this repository: no Glassdoor, no channel check, no outside commentary, no board claim row. That is the largest single gap on this name and it will stay open until that slot runs.
• The ~$1.3bn Capital One shortfall is unexplained, not explained-away. This pass establishes the two numbers and that no filing reconciles them. The benign reading (five months of IRA attrition between signing and closing) is stated as the likely explanation and is not sourced to any document.
• No short interest (Equibles down), no analyst-coverage count (standing gap).
• The premium paid on both deposit acquisitions is undisclosed, so neither deal's economics can be computed.
• DEF 14A is the FY2025 one; compensation structure not extracted, ownership table only. Sixth consecutive name slot to leave the comp read.
• The FY2027 model's deposit-cost assumption is not sourced. Axos does not disclose the rate paid on the acquired IRA book, and the FY2026 average-balance table predates it.

Process support, not investment advice.